Compare
ARS Pharmaceuticals, Inc. vs Standard Biotools Inc. vs Cytokinetics Inc vs Eton Pharmaceuticals, Inc.
| Latest fiscal year | ARS Pharmaceuticals, Inc. SPRY | Standard Biotools Inc. LAB | Cytokinetics Inc CYTK | Eton Pharmaceuticals, Inc. ETON |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $84.28M | $85.33M | $88.04M | $79.95M |
| Revenue growth (YoY) | -5.5% | -6.2% | +376.6% | +104.9% |
| Gross margin | n/a | 49.9% | n/a | 53.5% |
| Operating margin | -212.9% | -129.2% | -695.4% | -1.1% |
| Net margin | -203.3% | -87.8% | -891.6% | -5.8% |
| Net income | -$171.30M | -$74.90M | -$784.96M | -$4.60M |
| EPS (Diluted) | -$1.74 | -$0.20 | -$6.54 | n/a |
| Operating cash flow | -$170.87M | -$74.34M | -$510.01M | $10.52M |
| Free cash flow | -$171.21M | -$82.65M | -$534.82M | $10.19M |
| Cash & equivalents | $41.32M | $120.86M | $122.52M | $25.94M |
| Total assets | $327.65M | $567.75M | $1.42B | $92.11M |
| Total liabilities | $213.39M | $143.46M | $2.08B | $65.96M |
| Shareholders' equity | $114.26M | $424.29M | -$659.62M | $26.15M |
| Return on year-end equity | -149.9% | -17.7% | n/a | -17.6% |
| Shares outstanding | 99.29M | 386.38M | 122.94M | 27.05M |
Revenue, most recent five fiscal years
| Fiscal year | ARS Pharmaceuticals, Inc. | Standard Biotools Inc. | Cytokinetics Inc | Eton Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $84.28M Ended 2025-12-31 | $85.33M Ended 2025-12-31 | $88.04M Ended 2025-12-31 | $79.95M Ended 2025-12-31 |
| 1 year earlier | $89.15M Ended 2024-12-31 | $91.01M Ended 2024-12-31 | $18.47M Ended 2024-12-31 | $39.01M Ended 2024-12-31 |
| 2 years earlier | $30.0K Ended 2023-12-31 | $106.34M Ended 2023-12-31 | $7.53M Ended 2023-12-31 | $31.64M Ended 2023-12-31 |
| 3 years earlier | $1.32M Ended 2022-12-31 | $97.95M Ended 2022-12-31 | $94.59M Ended 2022-12-31 | $21.25M Ended 2022-12-31 |
| 4 years earlier | $5.51M Ended 2021-12-31 | $130.58M Ended 2021-12-31 | $70.43M Ended 2021-12-31 | $21.83M Ended 2021-12-31 |